Key result
Vitamin E fails to reduce plasma ADMA levels in patients with chronic kidney disease.
Why the study?
Does vitamin E reduce plasma ADMA levels in patients with non-diabetic CKD?
Does vitamin E reduce plasma ADMA levels in patients with non-diabetic CKD?
p-value: p=0.16
Vitamin E supplementation may lower ADMA levels in a subset of patients with severe non-diabetic CKD, potentially improving nitric oxide bioavailability.
No takes yet. Share an insight, caveat, or question.
Vitamin E should not change ADMA management in CKD; leaves open possible subset benefit in non-diabetic patients for prospective trials.
Rajiv Saran (2003) studied chronic kidney disease (CKD) (n=14). Vitamin E (alpha-tocopherol) vs. Healthy controls was evaluated on Plasma ADMA levels (p=0.16). Vitamin E (800 IU for 8 weeks) did not significantly reduce overall plasma ADMA levels in patients with chronic kidney disease (overall P=0.16), despite a 23% decrease in 6 of 8 patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: